scholarly journals Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Maria Giner-Soriano ◽  
Josep Ramon Marsal ◽  
Ainhoa Gomez-Lumbreras ◽  
Rosa Morros

Abstract Background Cerebrovascular disorders have occurred more frequently in some Central Nervous System (CNS) disorders, such as epilepsy. Some CNS drugs have been associated with increased stroke risk. Our aim was to estimate the risk of ischaemic stroke in patients exposed to antiepileptic drugs (AED). Methods Population-based matched case-control study using SIDIAP database, based in electronic health records from primary healthcare from Catalonia, Spain. Cases were those patients with a registered diagnosis of first stroke during 2009–2014. Up to 10 controls were selected for each case and matched by sex, age, and geographic area and without a prior diagnosis of stroke. We considered global drug exposure to AED, past and current exposure and exposure in monotherapy to each AED. Results 2,865 cases and 19,406 controls were exposed to AED during the study period. Global exposure to levetiracetam [(ORadj3.3, CI95 % 2.8-4.0)], phenytoin [ORadj1.5, CI95 % 1.2–41.9)], and valproic acid [(ORadj 1.3, CI95 % 1.1–1.6)], showed significantly association to ischaemic stroke that was also maintained with current exposure of levetiracetam [ORadj4.1, CI95 % 3.3–5.2)] and valproic acid [ORadj1.4, CI95 % 1.1–1.9)]. Current levetiracetam monotherapy showed a very high risk of ischaemic stroke [(ORadj 5.1, CI95 % 3.7–6.9)]. Conclusions Drugs used for other conditions than epilepsy (pregabalin, gabapentin) were the most used AED and both did not show a risk. Levetiracetam shows a risk for stroke even when assessed in current monotherapy. The lack of data regarding the link with diagnosis and severity in our study makes it necessary to conduct further studies to confirm or dismiss our results, focussing on levetiracetam.

Seizure ◽  
2018 ◽  
Vol 59 ◽  
pp. 28-33 ◽  
Author(s):  
Henrik Falhammar ◽  
Jonatan D. Lindh ◽  
Jan Calissendorff ◽  
Shermineh Farmand ◽  
Jakob Skov ◽  
...  

2019 ◽  
Vol 53 (11) ◽  
pp. 1102-1110 ◽  
Author(s):  
Siin Kim ◽  
Sang-Myung Cheon ◽  
Hae Sun Suh

Background: Although drug-induced parkinsonism is reversible in most cases, some patients can suffer from persistent/recurrent symptoms. Therefore, prevention is the most efficient way to manage drug-induced parkinsonism. However, there is a paucity of studies exploring the relationship between parkinsonism and drug exposure. Objective: To examine the association between drug exposure and the risk of parkinsonism using Korean population-based data. Methods: We conducted a matched case-control study using the National Health Insurance Service—National Sample Cohort database. Cases and controls were defined as individuals with and without parkinsonism, respectively, between 2007 and 2013. Cases and controls were matched for sex, age group, income, type of insurance, and Charlson comorbidity index. Drug exposures, including propulsives, antipsychotics, and flunarizine, were identified at 1 year before the first date of parkinsonism and stratified by recency and cumulative dose. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% CIs. Results: We identified 5496 cases and 5496 controls. ORs for current use group of propulsives, antipsychotics, and flunarizine compared with those of the never use group were 2.812 (95% CI = 2.466-3.206), 3.009 (95% CI = 1.667-5.431), and 4.950 (95% CI = 2.711-9.037), respectively. ORs were greater in those more recently exposed and those exposed to higher cumulative doses. Conclusion and Relevance: At the population level, use of propulsives, antipsychotics, and flunarizine had a significant association with the increased risk of parkinsonism, depending on recency and cumulative dose. Drugs associated with parkinsonism should be used with careful monitoring to prevent drug-induced parkinsonism.


2006 ◽  
Vol 13 (2) ◽  
pp. 113-117 ◽  
Author(s):  
Mette N??rgaard ◽  
Jacob Jacobsen ◽  
Chaveewan Ratanajamit ◽  
Peter Jepsen ◽  
Joseph K. McLaughlin ◽  
...  

F1000Research ◽  
2013 ◽  
Vol 2 ◽  
pp. 145 ◽  
Author(s):  
Sonal Singh ◽  
Hsien Yen Chang ◽  
Thomas Richards ◽  
Jonathan P Weiner ◽  
Jeanne M Clark ◽  
...  

Objective: Previous randomized clinical trials and their meta-analyses have raised the possibility that thiazolidinediones (rosiglitazone and pioglitazone) may increase the risk of pneumonia. We aimed to test the hypothesis that thiazolidinediones may increase the risk of pneumonia.Design: Population based case-control study using a new user design.Setting: A large administrative database in the United States from 2002 to 2008.Population: Adults with type 2 diabetes aged 18-64; restricted to 6129 hospitalized pneumonia cases and 6129 controls without congestive heart failure matched on age, sex, enrollment pattern and diabetes complication severity index matched controls. Conditional logistic regression was used to analyse the data.Results: Compared with controls, cases were more likely to have chronic obstructive pulmonary disease (COPD), tobacco use, cancer and have received influenza and pneumococcal vaccination. After adjusting for COPD, cancer, tobacco use, and receipt of influenza and pneumococcal vaccination, and exposure in other periods, neither recent exposure to pioglitazone (adjusted Odds Ratio [aOR], 1.15, 95% Confidence intervals 1.00 – 1.32) or rosiglitazone (aOR 1.09, 95% CI, 0.83 – 1.44) nor current exposure to pioglitazone within 60 days (aOR, 1.04, 95% CI, 0.60 – 1.79) was associated with a statistically significant odds of pneumonia. Current exposure to rosiglitazone was associated with a statistically significant reduction in the odds of pneumonia (aOR, 0.33, 95% CI 0.11-0.95).Conclusion: In this study of US adults with type 2 diabetes we did not detect a significant increased risk of pneumonia with the thiazolidinediones. The unusually large protective effect of current exposure to rosiglitazone reflects the healthy user effect or unmeasured confounding.


2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Valentino Conti ◽  
Mauro Venegoni ◽  
Alfredo Cocci ◽  
Ida Fortino ◽  
Antonio Lora ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 146-146
Author(s):  
Eric J. Bergstralh ◽  
Rosebud O. Roberts ◽  
Michael M. Lieber ◽  
Sara A. Farmer ◽  
Jeffrey M. Slezak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document